ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
Early clinical experience with IPX203 in Parkinson's disease with motor fluctuations.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motor fluctuations remain a major challenge in the treatment of Parkinson's disease (PD). IPX203 is a novel extended-release formulation of levodopa/carbidopa designed to provide rapid onset of benefit while maintaining therapeutic levodopa concentrations for a longer duration than immediate-release formulations. This review summarizes the formulation, pharmacokinetic profile, and clinical efficacy of IPX203 and discusses early clinical experience following its introduction into routine practice in the United States. Phase 2 studies demonstrated rapid levodopa absorption and prolonged plasma exposure, while the phase 3 RISE-PD trial showed significantly greater Good ON time with fewer daily doses compared with optimized immediate-release levodopa/carbidopa. The unique formulation combines immediate-release granules with mucoadhesive extended-release pellets that prolong levodopa delivery within the proximal small intestine. Early clinical experience suggests that many patients achieve meaningful improvements in motor fluctuations, treatment convenience, and overnight symptom control following conversion to IPX203. Three representative patient vignettes illustrate common clinical scenarios and practical approaches to treatment optimization. IPX203 provides a novel oral levodopa/carbidopa delivery strategy that combines rapid onset with prolonged duration of benefit. Clinical trial data and early clinical experience support its use as an effective option for patients with PD experiencing motor fluctuations and highlight the importance of individualized treatment optimization to maximize therapeutic benefit.
Indexed as
Identifiers
42771219What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.